Characteristics of patient samples.
M, male; F, female. # × 109/L
| AML sample | Gender | Age (yr) | WHO subtype | WBC count# | % Blasts in PB | % Blasts in BM | Karyotype | Additional molecular features |
|---|---|---|---|---|---|---|---|---|
| #1 | M | 28 | AML without maturation | 143 | 98 | 90 | 46, XY | FLT3-ITD |
| #2 | M | 40 | AML without maturation | 52 | 66 | 80 | 46,XY | Biallelic CEBPA mutation |
| #3 | F | 34 | AML with myelodysplasia-related changes | 32 | 16 | 44 | 45,XX, -7 | FLT3wt NPMwt |
| #4 | M | 45 | AML with t(6,9) | 40 | 58 | 43 | 46,XY,t(6;9)(p23;q34) | FLT3-ITD |
| #5 | M | 48 | AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 | 54 | 5 | 24 | 46,XY,t(8;21)(q22;q22) | NPMwt / FLT3 N/A |
| #6 | M | 61 | AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 | 21.4 | 51 | 89 | 45,X-Y,t(8;21)(q22;q22)[19]/46,XY[1] | FLT3wt NPMwt |
| #7 | F | 58 | AML with myelodysplasia-related changes | 100.7 | 45 | 80 | 46,XX,del(5)(q23q33), t(8;9)(p11;q34)[20] | FLT3wt NPMwt |
| #8 | M | 24 | AML with myelodysplasia-related changes | 7.1 | 83 | 30 | 46,XY[20] | FLT3wt NPMwt |
| #9 | M | 49 | AML with myelodysplasia-related changes | 76.4 | 42 | 26 | 46-47,XY,del(5)(q22q34),del(6)(q22q25),del(7)(q22q23),-8,-9,add(11)(q23),+i(11)(q11),-16,+mar1,+mar2,+mar3[cp8]. | FLT3wt NPMwt |
| #10 | M | 22 | AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 | 20.4 | 83 | 69 | 45,X,-Y,t(8;21)(q22;q22)[17]/46,XY[3] | FLT3 ITD |
| #11 | F | 60 | AML with myelodysplasia-related changes | 218.1 | 68 | 36 | 48,XX,+8,+21[13] | FLT3wt NPMwt |